Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting injectable bromocriptine does not reduce relapse in alcoholics

C A Naranjo1, M Dongier, K E Bremner

  • 1Psychopharmacology Research Program, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada. naranjo@owl.sunnybrook.utoronto.ca

Addiction (Abingdon, England)
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term health care costs for prostate cancer patients on androgen deprivation therapy.

Current oncology (Toronto, Ont.)·2016
Same author

Population-based trends in systemic therapy use and cost for cancer patients in the last year of life.

Current oncology (Toronto, Ont.)·2016
Same author

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Current oncology (Toronto, Ont.)·2014
Same author

A clinical pharmacologic perspective on the detection and assessment of adverse drug reactions.

Drug information journal·2014
Same author

Cytogenetic studies in the genus Zea : 1. Evidence for five as the basic chromosome number.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

Cytogenetic studies in the genus Zea : 2. Colchicine-induced multivalents.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013

This study found that bromocriptine, a dopamine agonist, did not effectively reduce relapse in alcohol dependence. Long-acting injectable bromocriptine (Parlodel-LAR) showed no significant benefit over placebo for maintaining abstinence.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Medicine

Background:

  • Dopamine neurotransmission plays a role in alcohol consumption and dependence.
  • Previous studies suggested bromocriptine might aid in alcohol withdrawal and dependence management.

Purpose of the Study:

  • To evaluate the efficacy of long-acting injectable bromocriptine (Parlodel-LAR) in preventing relapse among individuals with moderate to severe alcohol dependence.
  • To assess bromocriptine's effectiveness in maintaining abstinence or reducing drinking levels.

Main Methods:

  • A randomized, double-blind, placebo-controlled international multicenter study.
  • 366 participants with alcohol dependence received six monthly injections of bromocriptine (25 mg or 50 mg) or placebo post-detoxification.
  • Brief psychosocial treatment was permitted.

Related Experiment Videos

Main Results:

  • No significant differences were observed between bromocriptine and placebo groups in relapse rates at 6 months.
  • Relapse was defined as any drinking or drinking on 5+ days/month with 3+ drinks/day.
  • Adverse events and efficacy ratings did not differ significantly across treatment arms.

Conclusions:

  • Long-acting injectable bromocriptine is not efficacious in maintaining abstinence or reducing drinking in alcohol-dependent individuals.
  • The study's findings contrast with some prior research, suggesting further investigation into discrepancies.
  • Compliance was enhanced by the long-acting injectable formulation, but this did not translate to clinical efficacy.